University of Navarra

Shionogi Strengthens Regulatory Leadership with the Appointment of Dr. Ramón Polo as Senior Vice President, Head of Regulatory Affairs

Retrieved on: 
Monday, February 5, 2024

Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of Ramón Polo, MBA, PharmD, Ph.D. as Senior Vice President, Head of Regulatory Affairs.

Key Points: 
  • Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of Ramón Polo, MBA, PharmD, Ph.D. as Senior Vice President, Head of Regulatory Affairs.
  • He joins Shionogi Inc. from Johnson & Johnson, where he served as the Vice President, Head of Infectious Diseases, Vaccines & Global Public Health Regulatory Affairs.
  • Prior to this, Dr. Polo led the development strategy of treatments for influenza, RSV and hepatitis C at Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Dr. Polo received his PharmD, Master of Science and Ph.D. in Clinical Biochemistry from the Complutense University of Madrid in Spain.

Mission Bio Announces Over 20 Presentations Demonstrating the Utility of Tapestri Across AML, Multiple Myeloma, and Lymphoma at the 2023 ASH Annual Meeting

Retrieved on: 
Thursday, December 7, 2023

The widespread adoption of Tapestri for hematological research and therapeutic development signifies the importance of single-cell multi-omic data and indicates a potential new gold standard in precision medicine.

Key Points: 
  • The widespread adoption of Tapestri for hematological research and therapeutic development signifies the importance of single-cell multi-omic data and indicates a potential new gold standard in precision medicine.
  • Detected MRD-positive patients, which were deemed negative by MFC and PCR,
    Differentiated between clonal hematopoiesis (CH) clones and leukemic clones.
  • Data from other blood cancer studies will be presented by leading researchers in over 24 presentations leveraging Mission Bio’s Tapestri Platform, showcasing its broad application in hematology.
  • For a complete list of ASH presentations using Tapestri, please visit our website .

BE OPEN Congratulates the Winners of 'Better Energy by Design' Competition Focused on the United Nations SDG7

Retrieved on: 
Wednesday, July 5, 2023

London, United Kingdom--(Newsfile Corp. - July 5, 2023) - Better Energy by Design was the latest design competition developed by philanthropic initiative BE OPEN.

Key Points: 
  • London, United Kingdom--(Newsfile Corp. - July 5, 2023) - Better Energy by Design was the latest design competition developed by philanthropic initiative BE OPEN.
  • These competitions are open to students, graduates and young professionals in the fields of art, design, architecture and media.
  • The focus of the latest competition was the United Nations SDG7: Affordable and Clean Energy.
  • Entrants were invited to explore how to make clean energy technologies affordable, more efficient or more appealing to energy users.

BE OPEN congratulates the first winners of Better Energy by Design competition focused on SDG#7

Retrieved on: 
Monday, July 3, 2023

LONDON, July 3, 2023 /PRNewswire/ -- Better Energy by Design is the latest of design competitions developed by philanthropic initiative BE OPEN.

Key Points: 
  • LONDON, July 3, 2023 /PRNewswire/ -- Better Energy by Design is the latest of design competitions developed by philanthropic initiative BE OPEN.
  • These competitions are open to students, graduates and young professionals in the fields of art, design, architecture and media.
  • The programme aims to encourage creation of innovative solutions by younger creatives, for a more prosperous and sustainable future.
  • Achievement of SDG7 is impossible without ensuring that a growing number of households, communities and production companies use green energy technologies.

BE OPEN congratulates the first winners of Better Energy by Design competition focused on SDG#7

Retrieved on: 
Monday, July 3, 2023

LONDON, July 3, 2023 /PRNewswire/ -- Better Energy by Design is the latest of design competitions developed by philanthropic initiative BE OPEN.

Key Points: 
  • LONDON, July 3, 2023 /PRNewswire/ -- Better Energy by Design is the latest of design competitions developed by philanthropic initiative BE OPEN.
  • These competitions are open to students, graduates and young professionals in the fields of art, design, architecture and media.
  • The programme aims to encourage creation of innovative solutions by younger creatives, for a more prosperous and sustainable future.
  • Achievement of SDG7 is impossible without ensuring that a growing number of households, communities and production companies use green energy technologies.

IESE Research Unveils Power of Corporate Venturing Squads in Driving Innovation

Retrieved on: 
Tuesday, June 13, 2023

MADRID, June 13, 2023 /PRNewswire/ -- IESE Business School, in collaboration with Kapita, has released a report on the innovation benefits of corporate venturing squads – the practice of a group of corporations joining forces to innovate with one or more startups.

Key Points: 
  • MADRID, June 13, 2023 /PRNewswire/ -- IESE Business School, in collaboration with Kapita, has released a report on the innovation benefits of corporate venturing squads – the practice of a group of corporations joining forces to innovate with one or more startups.
  • The report, titled " Open Innovation: Corporate Venturing Squads ," co-authored by IESE Business School professor Mª Julia Prats as well as Josemaria Siota, Carla Bustamante, and Beatriz Camacho from IESE's Open Innovation and Corporate Venturing Institute , explores the benefits and strategies employed by these squads to enhance innovation.
  • The research analyzed 50 corporate venturing squads, involving 340 squad members and 262 corporations, and conducted interviews with 50 chief innovation officers across Europe, Asia, and America.
  • To learn more about the power of corporate venturing squads in driving innovation, access the full report .

IESE Research Unveils Power of Corporate Venturing Squads in Driving Innovation

Retrieved on: 
Tuesday, June 13, 2023

MADRID, June 13, 2023 /PRNewswire/ -- IESE Business School, in collaboration with Kapita, has released a report on the innovation benefits of corporate venturing squads – the practice of a group of corporations joining forces to innovate with one or more startups.

Key Points: 
  • MADRID, June 13, 2023 /PRNewswire/ -- IESE Business School, in collaboration with Kapita, has released a report on the innovation benefits of corporate venturing squads – the practice of a group of corporations joining forces to innovate with one or more startups.
  • The report, titled " Open Innovation: Corporate Venturing Squads ," co-authored by IESE Business School professor Mª Julia Prats as well as Josemaria Siota, Carla Bustamante, and Beatriz Camacho from IESE's Open Innovation and Corporate Venturing Institute , explores the benefits and strategies employed by these squads to enhance innovation.
  • The research analyzed 50 corporate venturing squads, involving 340 squad members and 262 corporations, and conducted interviews with 50 chief innovation officers across Europe, Asia, and America.
  • To learn more about the power of corporate venturing squads in driving innovation, access the full report .

Dr. Jack Kolenda from Toronto and Lux Vitae Worldwide Announce That The Steriwave Nasal Decolonization Treatment Has Been Successfully Used By The Rock Band KISS Since September of 2021, To Prevent The Transmission And Spread of Covid 19

Retrieved on: 
Sunday, March 5, 2023

The legendary manager of KISS, Doc McGhee, had heard about the Steriwave nasal decolonization treatment and after substantial due diligence, made the decision to deploy the Steriwave treatment on the KISS world tour.

Key Points: 
  • The legendary manager of KISS, Doc McGhee, had heard about the Steriwave nasal decolonization treatment and after substantial due diligence, made the decision to deploy the Steriwave treatment on the KISS world tour.
  • Several of these patients, will be present at the press conference to report on their personal experiences with the Steriwave treatment.
  • With this information, Dr. Kolenda initiated the use of the Steriwave for treatment for his staff and patients to prevent the transmission and spread of Covid 19.
  • Highly importantly, none of the Covid 19 positive patients treated with the Steriwave treatment were admitted to hospital.

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium

Retrieved on: 
Monday, October 17, 2022

We look forward to presenting our data at an international forum with other world-renowned leaders in MS and immunotherapy, said Dr. Tiago Reis Marques, CEO, Pasithea.

Key Points: 
  • We look forward to presenting our data at an international forum with other world-renowned leaders in MS and immunotherapy, said Dr. Tiago Reis Marques, CEO, Pasithea.
  • The study results support the Companys ongoing commitment to the program and move us further along in our mission to uncover new and effective treatments for neurological disorders.
  • The field of neurology, particularly for disabling diseases such as MS, requires deep research into the nature of effective therapeutic and immunization solutions.
  • Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders.

Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships

Retrieved on: 
Tuesday, December 21, 2021

Dr Trilla will apply the knowledge gained from his experience collaborating on over 160 life science partnerships to oversee corporate strategy, business partnerships and lead Intrommune through our business planning process.

Key Points: 
  • Dr Trilla will apply the knowledge gained from his experience collaborating on over 160 life science partnerships to oversee corporate strategy, business partnerships and lead Intrommune through our business planning process.
  • I am confident that my background as a licensed physician and global entrepreneur distinguishes me as an ideal leader for Intrommune, said Sergi Trilla, MD, MBA, Director of Corporate Strategy & Partnerships, Intrommune.
  • My decades of life science business experience will help advance Intrommune and its OMIT food allergy technology platform.
  • My expertise in international healthcare business also provides a perspective to help Intrommune in its global product and corporate development and partnerships, added Trilla.